Literature DB >> 27077227

Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53.

Wen-Ting Liu1, Ying-Ying Jing1, Guo-feng Yu2, Hong Chen3, Zhi-peng Han1, Dan-Dan Yu1, Qing-Min Fan4, Fei Ye1, Rong Li1, Lu Gao1, Qiu-Dong Zhao1, Meng-Chao Wu5, Li-Xin Wei1.   

Abstract

The biological behaviors of hepatocellular carcinoma (HCC) are complex mainly due to heterogeneity of progressive genetic and epigenetic mutations as well as tumor environment. Hepatocyte growth factor (HGF)/c-Met signaling pathway is regarded to be a prototypical example for stromal-epithelial interactions during developmental morphogenesis, wound healing, organ regeneration and cancer progression. And p53 plays as an important regulator of Met-dependent cell motility and invasion. Present study showed that 2 HCC cell lines, Hep3B and HepG2, displayed different invasive capacity when treated with HGF which was secreted by hepatic stellate cells (HSCs). We found that HGF promoted Hep3B cells invasion and migration as well as epithelial-mesenchymal transition (EMT) occurrence because Hep3B was p53 deficient, which leaded to the c-Met over-expression. Then we found that HGF/c-Met promoted Hep3B cells invasion and migration by upregulating Snail expression. In conclusion, HGF/c-Met signaling is enhanced by loss of p53 expression, resulting in increased ability of invasion and migration by upregulating the expression of Snail.

Entities:  

Keywords:  EMT; HGF/c-Met; HSCs; hepatocellular carcinoma; invasion and migration; p53

Mesh:

Substances:

Year:  2016        PMID: 27077227      PMCID: PMC4889302          DOI: 10.1080/15384101.2016.1152428

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  33 in total

1.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

2.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

3.  Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.

Authors:  Clifford G Tepper; Jeffrey P Gregg; Xu-Bao Shi; Ruth L Vinall; Colin A Baron; Philip E Ryan; Pierre-Yves Desprez; Hsing-Jien Kung; Ralph W deVere White
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

4.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.

Authors:  Silvia Di Agostino; Sabrina Strano; Velia Emiliozzi; Valentina Zerbini; Marcella Mottolese; Ada Sacchi; Giovanni Blandino; Giulia Piaggio
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

5.  Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells.

Authors:  C Tan; P Costello; J Sanghera; D Dominguez; J Baulida; A G de Herreros; S Dedhar
Journal:  Oncogene       Date:  2001-01-04       Impact factor: 9.867

Review 6.  Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever.

Authors:  Vinicio Carloni; Tu Vinh Luong; Krista Rombouts
Journal:  Liver Int       Date:  2014-02-12       Impact factor: 5.828

Review 7.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

8.  Transcriptional repressor snail and progression of human hepatocellular carcinoma.

Authors:  Keishi Sugimachi; Shinji Tanaka; Toshifumi Kameyama; Ken-ichi Taguchi; Shin-ichi Aishima; Mitsuo Shimada; Keizo Sugimachi; Masazumi Tsuneyoshi
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

9.  An epithelial scatter factor released by embryo fibroblasts.

Authors:  M Stoker; M Perryman
Journal:  J Cell Sci       Date:  1985-08       Impact factor: 5.285

Review 10.  The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis.

Authors:  R Zarnegar; G K Michalopoulos
Journal:  J Cell Biol       Date:  1995-06       Impact factor: 10.539

View more
  14 in total

Review 1.  AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.

Authors:  Chih-Hung Hsu; Yi-Hsiang Huang; Shi-Ming Lin; Chiun Hsu
Journal:  Liver Cancer       Date:  2022-02-10       Impact factor: 12.430

Review 2.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

3.  Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.

Authors:  Katharina M Schmidt; Peter Dietrich; Christina Hackl; Jessica Guenzle; Peter Bronsert; Christine Wagner; Stefan Fichtner-Feigl; Hans J Schlitt; Edward K Geissler; Claus Hellerbrand; Sven A Lang
Journal:  Neoplasia       Date:  2018-11-04       Impact factor: 5.715

Review 4.  Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma.

Authors:  Long Yan; Feng Xu; Chao-Liu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-08-29

5.  High-Affinity Human Anti-c-Met IgG Conjugated to Oxaliplatin as Targeted Chemotherapy for Hepatocellular Carcinoma.

Authors:  Yilan Ma; Mingjiong Zhang; Jiayan Wang; Xiaochen Huang; Xingwang Kuai; Xiaojuan Zhu; Yuan Chen; Lizhou Jia; Zhenqing Feng; Qi Tang; Zheng Liu
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

6.  Correlations of microvascular blood flow of contrast-enhanced ultrasound and HGF/c-Met signaling pathway with clinicopathological features and prognosis of patients with hepatocellular carcinoma.

Authors:  Peng-Hui Zhuang; Lei Xu; Lu Gao; Wei Lu; Li-Tao Ruan; Jin Yang
Journal:  Onco Targets Ther       Date:  2017-02-14       Impact factor: 4.345

Review 7.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.

Authors:  Yazhuo Zhang; Mengfang Xia; Ke Jin; Shufei Wang; Hang Wei; Chunmei Fan; Yingfen Wu; Xiaoling Li; Xiayu Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

Review 8.  Multipotent mesenchymal stromal cells play critical roles in hepatocellular carcinoma initiation, progression and therapy.

Authors:  Zeli Yin; Keqiu Jiang; Rui Li; Chengyong Dong; Liming Wang
Journal:  Mol Cancer       Date:  2018-12-28       Impact factor: 27.401

9.  Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma.

Authors:  Nataša Pavlović; Carlemi Calitz; Kess Thanapirom; Guiseppe Mazza; Krista Rombouts; Pär Gerwins; Femke Heindryckx
Journal:  Elife       Date:  2020-10-26       Impact factor: 8.140

10.  Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.

Authors:  Alex J Eustace; Bryan T Hennessy; Sean P Kennedy; Michael O'Neill; Darren Cunningham; Patrick G Morris; Sinead Toomey; Carmen Blanco-Aparicio; Sonia Martinez; Joaquin Pastor
Journal:  Oncogene       Date:  2020-02-10       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.